Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / MOR - FDA OKs Incyte/Morphosys' tafasitamab for treatment-resistant lymphoma


MOR - FDA OKs Incyte/Morphosys' tafasitamab for treatment-resistant lymphoma

  • Morphosys AG (NASDAQ:MOR) and collaboration partner/licensee Incyte (NASDAQ:INCY) announce the FDA nod for Monjuvi (tafasitamab-cxix), combined with lenalidomide, for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.
  • More news on: MorphoSys AG, Incyte Corporation, MorphoSys AG, Healthcare stocks news,
  • Read more ...
Stock Information

Company Name: MorphoSys AG
Stock Symbol: MOR
Market: NASDAQ
Website: morphosys.com

Menu

MOR MOR Quote MOR Short MOR News MOR Articles MOR Message Board
Get MOR Alerts

News, Short Squeeze, Breakout and More Instantly...